Jilin Yatai Pharmaceutical

Jilin Yatai Pharmaceutical, a core subsidiary of the Jilin Yatai Group, is a China-based pharmaceutical company specializing in the research, development, and manufacturing of anti-tumor drugs and modernized traditional Chinese medicine. The company is most notable for its flagship product, Shenyi Capsule (Ginsenoside Rg3), which is recognized as a first-class new drug in China for its ability to inhibit tumor angiogenesis. Beyond oncology, the company maintains a portfolio of chemical drugs and biological products targeting cardiovascular and infectious diseases. Jilin Yatai Pharmaceutical operates large-scale, GMP-certified manufacturing facilities and integrates advanced extraction technologies to produce high-purity natural medicinal compounds.